|1.||Anadón, Arturo: 1 article (02/2011)|
|2.||Gamboa, Felipe: 1 article (02/2011)|
|3.||Ares, Irma: 1 article (02/2011)|
|4.||Martínez-Larrañaga, María R: 1 article (02/2011)|
|5.||Suárez, Frank H: 1 article (02/2011)|
|6.||Ramos, Eva: 1 article (02/2011)|
|7.||Martínez, Marta: 1 article (02/2011)|
|8.||Castellano, Víctor: 1 article (02/2011)|
|9.||Martínez, María A: 1 article (02/2011)|
|10.||Stephens, Dennis: 1 article (08/2004)|
06/01/2002 - "Efficacy of sarafloxacin in broilers after experimental infection with Escherichia coli."
06/01/2002 - "The birds were given 5 and 10 mg/kg per day sarafloxacin in each group, starting within 2 h after infection. "
06/01/2002 - "In the first experiment, sarafloxacin (20 mg/L, equivalent to 5 mg/kg live weight per day), given in the drinking water for 3 days after infection, led to a reduction in the mortality from 75% to 27%, but the ADG of the treated birds was still less than that of the uninfected controls. "
06/01/2002 - "Infections of chickens with Escherichia coli serotype O78 can be treated with the antibiotic sarafloxacin. "
09/01/1998 - "Sarafloxacin (formerly A-56620) is a fluoroquinolone recently introduced into veterinary practice for the therapy of colibacillosis and other indicated infections. "
02/01/1986 - "coli or Pseudomonas pyelonephritis in mice was more effectively treated with A-56619 or A-56620 than with norfloxacin. "
02/01/1986 - "A-56619 and A-56620 were also more potent than norfloxacin in treatment of mixed bacterial pyelonephritis caused by E. "
04/01/1987 - "coli pyelonephritis in mice was treated with the fluoroquinolones, difloxacin, A-56620, and ciprofloxacin were more effective than norfloxacin and nalidixic acid in lowering viable bacterial counts in the kidneys. "
|4.||Body Weight (Weight, Body)
02/01/2011 - "Chickens were used to investigate plasma disposition of difloxacin after single intravenous (IV) and oral dose (10 mg/kg body weight (BW)) and to study residue depletion of difloxacin and its major metabolite sarafloxacin after multiple oral doses (10 mg difloxacin/kg BW, daily for 5 days). "
05/01/1995 - "Taking the different dosages (25 mg/kg of body weight for oxolinic acid and flumequine and 10 mg/kg for sarafloxacin and enrofloxacin) into account, enrofloxacin showed the highest maximum concentration in plasma, followed by flumequine, oxolinic acid, and sarafloxacin. "
01/01/1987 - "The in vitro activity of two new quinolones, difloxacin and A-56620, was compared with that of other quinolones against isolates obtained from bacteremic cancer patients. "
01/01/1987 - "In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients."
01/01/1988 - "The in vitro activity of Fleroxacin (Ro23-6240; AM 833), a new fluorinated 4-quinolone, was compared to that of ciprofloxacin, enoxacin and A-56620, against 747 isolates from cancer patients. "
01/01/1987 - "The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. "
|5.||4-Quinolones (4 Quinolones)
|6.||Enoxacin (AT 2266)
|9.||Triamcinolone Acetonide (Azmacort)